Future studies using hepatocyte-specific ACSL3 KO models and more selective inhibitors are essential to confirm the therapeutic potential of targeting ACSL3 in MASLD. The gene discussed is ACSL3; the disease is metabolic dysfunction-associated steatotic liver disease.